Wedbush Keeps a Hold Rating on Sangamo Biosciences (SGMO)

By Austin Angelo

Wedbush analyst Liana Moussatos reiterated a Hold rating on Sangamo Biosciences (NASDAQ: SGMO) today and set a price target of $10. The company’s shares opened today at $14.80.

According to, Moussatos is a 3-star analyst with an average return of 1.5% and a 42.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $10.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.64 million. In comparison, last year the company had a GAAP net loss of $12.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II on June 22, 1995 and is headquartered in Richmond, CA.